Form 4: Nektar Therapeutics Chief Legal Officer Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Mark A. Wilson, Chief Legal Officer of Nektar Therapeutics, sold 6,260 shares of common stock on May 17, 2024, to cover tax withholding obligations related to vesting RSUs.
Summary
- On May 17, 2024, Mark A. Wilson, the Chief Legal Officer of Nektar Therapeutics, sold 6,260 shares of the company's common stock.
- The sale was executed to cover required tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- The shares were sold at a weighted average price of $1.75, with individual transactions ranging from $1.72 to $1.80.
- Following the transaction, Wilson beneficially owns 230,414 shares, including 6,107 shares held in the Issuer's ESPP plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider stock sale for tax purposes, which is a neutral event.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their company's stock. It is common for executives to sell shares to cover tax obligations when stock options or restricted stock units vest.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date of the stock sale transaction. |
| 05/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.